Therefore, downregulating AGPAT3 expression or blocking its enzymatic product, phosphatidic acid, from binding to mTOR might be considered therapeutic approaches to overcome cisplatin chemoresistance in ovarian cancer, which has fewer side effects than other classes of mTOR inhibitors do [7]. Here, AGPAT3 is linked to ovarian carcinoma.